Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Irvin

Showing results (41-50 of 47) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 47 results.
Journal of the Pediatric Infectious Diseases Society|October 1, 2024
Safety and Pharmacokinetics of Casirivimab and Imdevimab (CAS + IMD) in Pediatric Outpatients With COVID-19Thomas D Norton, Mazhar Thakur, Samit Ganguly, et al.
The AAPS Journal|September 4, 2024
Correction to: Neutralizing Antibody Sample Testing and Report HarmonizationDarshana Jani, Michele Gunsior, Robin Marsden, et al.
The AAPS Journal|July 11, 2024
Neutralizing Antibody Sample Testing and Report HarmonizationDarshana Jani, Michele Gunsior, Robin Marsden, et al.
The Lancet. Infectious Diseases|September 5, 2024
Effect of timing of casirivimab and imdevimab administration relative to mRNA-1273 COVID-19 vaccination on vaccine-induced SARS-CoV-2 neutralising antibody responses: a prospective, open-label, phase 2, randomised controlled trialFlonza Isa, Ana M Gonzalez Ortiz, Jonathan Meyer, et al.
The New England Journal of Medicine|October 14, 2025
DB-OTO Gene Therapy for Inherited DeafnessVassili Valayannopoulos, Manohar Bance, Daniela S Carvalho, et al.
The AAPS Journal|October 28, 2022
Anti-drug Antibody Sample Testing and Reporting HarmonizationDarshana Jani, Robin Marsden, Michele Gunsior, et al.
Bioanalysis|January 6, 2026
2025 White Paper on Recent Issues in Bioanalysis: Redosing Patients with AAV Gene Therapy; CRS Immunogenicity Risk; Shedding Assays; NHP Studies Immunogenicity; CMC vs Bioanalytical Assays; Artificial Intelligence-Powered Genomic Pipelines for NGS (<u>PART 3A</u> - Recommendations on Gene, Cell, and Vaccine Therapies Immunogenicity & Technologies; Biotherapeutics & Biosimilars Immunogenicity Assessment & Clinical Relevance <u>PART 3B</u> - Regulatory Agencies' Input on Immunogenicity/Technologies of Biotherapeutics, Gene, Cell & Vaccine Therapies)Omar Tounekti, Sophie Shubow, Sarah Wassmer, et al.
Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
Journal of the Pediatric Infectious Diseases Society|October 1, 2024
Safety and Pharmacokinetics of Casirivimab and Imdevimab (CAS + IMD) in Pediatric Outpatients With COVID-19Thomas D Norton, Mazhar Thakur, Samit Ganguly, et al.
The AAPS Journal|September 4, 2024
Correction to: Neutralizing Antibody Sample Testing and Report HarmonizationDarshana Jani, Michele Gunsior, Robin Marsden, et al.
The AAPS Journal|July 11, 2024
Neutralizing Antibody Sample Testing and Report HarmonizationDarshana Jani, Michele Gunsior, Robin Marsden, et al.
The Lancet. Infectious Diseases|September 5, 2024
Effect of timing of casirivimab and imdevimab administration relative to mRNA-1273 COVID-19 vaccination on vaccine-induced SARS-CoV-2 neutralising antibody responses: a prospective, open-label, phase 2, randomised controlled trialFlonza Isa, Ana M Gonzalez Ortiz, Jonathan Meyer, et al.
The New England Journal of Medicine|October 14, 2025
DB-OTO Gene Therapy for Inherited DeafnessVassili Valayannopoulos, Manohar Bance, Daniela S Carvalho, et al.
The AAPS Journal|October 28, 2022
Anti-drug Antibody Sample Testing and Reporting HarmonizationDarshana Jani, Robin Marsden, Michele Gunsior, et al.
Bioanalysis|January 6, 2026
2025 White Paper on Recent Issues in Bioanalysis: Redosing Patients with AAV Gene Therapy; CRS Immunogenicity Risk; Shedding Assays; NHP Studies Immunogenicity; CMC vs Bioanalytical Assays; Artificial Intelligence-Powered Genomic Pipelines for NGS (<u>PART 3A</u> - Recommendations on Gene, Cell, and Vaccine Therapies Immunogenicity & Technologies; Biotherapeutics & Biosimilars Immunogenicity Assessment & Clinical Relevance <u>PART 3B</u> - Regulatory Agencies' Input on Immunogenicity/Technologies of Biotherapeutics, Gene, Cell & Vaccine Therapies)Omar Tounekti, Sophie Shubow, Sarah Wassmer, et al.
Pageof 5